Home
BIOA
BIOA News

Latest BioAge Labs Inc. Common Stock (BIOA) News on September 29, 2025

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

GlobeNewswire

3 months ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

MT Newswires

3 months ago

BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

GlobeNewswire

3 months ago

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

GlobeNewswire

4 months ago

BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates

BioAge Labs completes IND-enabling studies for BGE-102

TipRanks

4 months ago

BioAge Labs completes IND-enabling studies for BGE-102

BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025

Insider Monkey

4 months ago

BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

GlobeNewswire

4 months ago

BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic

BioAge Labs to Present at Upcoming Investor Conferences

GlobeNewswire

4 months ago

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire

5 months ago

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest

Simply Wall St.

5 months ago

With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest

BioAge Labs, Inc. (BIOA): A Bull Case Theory

Insider Monkey

5 months ago

BioAge Labs, Inc. (BIOA): A Bull Case Theory

Several Insiders Invested In BioAge Labs Flagging Positive News

Simply Wall St.

6 months ago

Several Insiders Invested In BioAge Labs Flagging Positive News

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

GlobeNewswire

6 months ago

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

BioArctic receives Orphan Drug Designation for exidavnemab the US

PR Newswire

6 months ago

BioArctic receives Orphan Drug Designation for exidavnemab the US

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

GlobeNewswire

7 months ago

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioPharma Dive

8 months ago

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

MT Newswires

8 months ago

BioAge Labs Terminates Azelapra Development

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

GlobeNewswire

8 months ago

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

After an obesity stumble, BioAge reconnects with its longevity pipeline

Pharma Voice

8 months ago

After an obesity stumble, BioAge reconnects with its longevity pipeline

BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

9 months ago

BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BioAge Labs, Inc. (BIOA): A Bull Case Theory

Insider Monkey

9 months ago

BioAge Labs, Inc. (BIOA): A Bull Case Theory

BioAge and Novartis seek drug targets for ageing-related diseases

Pharmaceutical Technology

9 months ago

BioAge and Novartis seek drug targets for ageing-related diseases

MT Newswires

9 months ago

BioAge Labs Says it is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

GlobeNewswire

9 months ago

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

3 closely watched drugs that failed in the clinic

Pharma Voice

9 months ago

3 closely watched drugs that failed in the clinic

BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

Clinical Trials Arena

10 months ago

BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

MT Newswires

10 months ago

Top Premarket Decliners

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

Benzinga

10 months ago

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

MT Newswires

10 months ago

Jefferies Downgrades BioAge Labs to Hold From Buy, Adjusts Price Target to $7 From $42

MT Newswires

10 months ago

Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45

BioAge shares tumble after decision to halt obesity drug study

BioPharma Dive

10 months ago

BioAge shares tumble after decision to halt obesity drug study

MT Newswires

10 months ago

BioAge Labs Terminates Phase 2 Trial of Obesity Drug Candidate

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

GlobeNewswire

10 months ago

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

GlobeNewswire

10 months ago

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?

Insider Monkey

10 months ago

Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?

BioAge Labs to Present at Upcoming Investor Conferences

GlobeNewswire

10 months ago

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Reports Strong Q3 2024 Achievements

TipRanks

a year ago

BioAge Labs Reports Strong Q3 2024 Achievements

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

GlobeNewswire

a year ago

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BioAge Labs to Present at Jefferies London Healthcare Conference

GlobeNewswire

a year ago

BioAge Labs to Present at Jefferies London Healthcare Conference

Investing.com

a year ago

Wall Street analysts initiate coverage of BioAge Labs

Prediction: These 2 Stocks Could Soar in 2025

Motley Fool

a year ago

Prediction: These 2 Stocks Could Soar in 2025

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

Motley Fool

a year ago

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc

GuruFocus.com

a year ago

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

Motley Fool

a year ago

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October

This IPO Biotech Stock Could Be the Next Eli Lilly

Motley Fool

a year ago

This IPO Biotech Stock Could Be the Next Eli Lilly

MT Newswires

a year ago

BioAge Labs Raises $238.3 Million From IPO, Private Placement

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

GlobeNewswire

a year ago

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

Share on Social Networks: